1017 related articles for article (PubMed ID: 7475321)
21. Synthesis and biological activity of novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 2-Aryl-substituted benzimidazoles.
Roth T; Morningstar ML; Boyer PL; Hughes SH; Buckheit RW; Michejda CJ
J Med Chem; 1997 Dec; 40(26):4199-207. PubMed ID: 9435891
[TBL] [Abstract][Full Text] [Related]
22. The HEPT Analogue WPR-6 Is Active against a Broad Spectrum of Nonnucleoside Reverse Transcriptase Drug-Resistant HIV-1 Strains of Different Serotypes.
Xu W; Zhao J; Sun J; Yin Q; Wang Y; Jiao Y; Liu J; Jiang S; Shao Y; Wang X; Ma L
Antimicrob Agents Chemother; 2015 Aug; 59(8):4882-8. PubMed ID: 26055365
[TBL] [Abstract][Full Text] [Related]
23. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.
Witvrouw M; Pannecouque C; Switzer WM; Folks TM; De Clercq E; Heneine W
Antivir Ther; 2004 Feb; 9(1):57-65. PubMed ID: 15040537
[TBL] [Abstract][Full Text] [Related]
24. Biological and biochemical anti-HIV activity of the benzothiadiazine class of nonnucleoside reverse transcriptase inhibitors.
Buckheit RW; Fliakas-Boltz V; Decker WD; Roberson JL; Pyle CA; White EL; Bowdon BJ; McMahon JB; Boyd MR; Bader JP
Antiviral Res; 1994 Sep; 25(1):43-56. PubMed ID: 7529014
[TBL] [Abstract][Full Text] [Related]
25. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009).
de Béthune MP
Antiviral Res; 2010 Jan; 85(1):75-90. PubMed ID: 19781578
[TBL] [Abstract][Full Text] [Related]
26. Pyrido [1,2a] indole derivatives identified as novel non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
Taylor DL; Ahmed PS; Chambers P; Tyms AS; Bedard J; Duchaine J; Falardeau G; Lavallée JF; Brown W; Rando RF; Bowlin T
Antivir Chem Chemother; 1999 Mar; 10(2):79-86. PubMed ID: 10335402
[TBL] [Abstract][Full Text] [Related]
27. The phenylmethylthiazolylthiourea nonnucleoside reverse transcriptase (RT) inhibitor MSK-076 selects for a resistance mutation in the active site of human immunodeficiency virus type 2 RT.
Auwerx J; Stevens M; Van Rompay AR; Bird LE; Ren J; De Clercq E; Oberg B; Stammers DK; Karlsson A; Balzarini J
J Virol; 2004 Jul; 78(14):7427-37. PubMed ID: 15220416
[TBL] [Abstract][Full Text] [Related]
28. Is there a role for non-nucleoside reverse transcriptase inhibitors in the treatment of HIV infection?
Kilby JM; Saag MS
Infect Agents Dis; 1994 Dec; 3(6):313-23. PubMed ID: 7534192
[TBL] [Abstract][Full Text] [Related]
29. Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants.
Dykes C; Fox K; Lloyd A; Chiulli M; Morse E; Demeter LM
Virology; 2001 Jul; 285(2):193-203. PubMed ID: 11437654
[TBL] [Abstract][Full Text] [Related]
30. (Alkylamino) piperidine bis(heteroaryl)piperizine analogs are potent, broad-spectrum nonnucleoside reverse transcriptase inhibitors of drug-resistant isolates of human immunodeficiency virus type 1 (HIV-1) and select for drug-resistant variants of HIV-1IIIB with reduced replication phenotypes.
Olmsted RA; Slade DE; Kopta LA; Poppe SM; Poel TJ; Newport SW; Rank KB; Biles C; Morge RA; Dueweke TJ; Yagi Y; Romero DL; Thomas RC; Sharma SK; Tarpley WG
J Virol; 1996 Jun; 70(6):3698-705. PubMed ID: 8648704
[TBL] [Abstract][Full Text] [Related]
31. The NCI's AIDS antiviral drug screening program.
Yang SS
Leukemia; 1995 Oct; 9 Suppl 1():S9-11. PubMed ID: 7475324
[TBL] [Abstract][Full Text] [Related]
32. Antiviral activity of GW678248, a novel benzophenone nonnucleoside reverse transcriptase inhibitor.
Ferris RG; Hazen RJ; Roberts GB; St Clair MH; Chan JH; Romines KR; Freeman GA; Tidwell JH; Schaller LT; Cowan JR; Short SA; Weaver KL; Selleseth DW; Moniri KR; Boone LR
Antimicrob Agents Chemother; 2005 Oct; 49(10):4046-51. PubMed ID: 16189079
[TBL] [Abstract][Full Text] [Related]
33. Susceptibility of the porcine endogenous retrovirus to reverse transcriptase and protease inhibitors.
Qari SH; Magre S; García-Lerma JG; Hussain AI; Takeuchi Y; Patience C; Weiss RA; Heneine W
J Virol; 2001 Jan; 75(2):1048-53. PubMed ID: 11134319
[TBL] [Abstract][Full Text] [Related]
34. New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infections.
Pauwels R
Curr Opin Pharmacol; 2004 Oct; 4(5):437-46. PubMed ID: 15351347
[TBL] [Abstract][Full Text] [Related]
35. Combining New Non-Nucleoside Reverse Transcriptase Inhibitors (RTIs) with AZT Results in Strong Synergism against Multi-RTI-Resistant HIV-1 Strains.
Yu F; Li W; Wang L; Dai Y; Lu X; Wang Q; Xie L; Jiang S
Molecules; 2018 Jul; 23(7):. PubMed ID: 30004408
[TBL] [Abstract][Full Text] [Related]
36. Strategies in the Design and Development of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs).
Vanangamudi M; Palaniappan S; Kathiravan MK; Namasivayam V
Viruses; 2023 Sep; 15(10):. PubMed ID: 37896769
[TBL] [Abstract][Full Text] [Related]
37. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
Tisdale M; Kemp SD; Parry NR; Larder BA
Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5653-6. PubMed ID: 7685907
[TBL] [Abstract][Full Text] [Related]
38. Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains.
Li A; Ouyang Y; Wang Z; Cao Y; Liu X; Ran L; Li C; Li L; Zhang L; Qiao K; Xu W; Huang Y; Zhang Z; Tian C; Liu Z; Jiang S; Shao Y; Du Y; Ma L; Wang X; Liu J
J Med Chem; 2013 May; 56(9):3593-608. PubMed ID: 23540737
[TBL] [Abstract][Full Text] [Related]
39. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments.
Vingerhoets J; Azijn H; Fransen E; De Baere I; Smeulders L; Jochmans D; Andries K; Pauwels R; de Béthune MP
J Virol; 2005 Oct; 79(20):12773-82. PubMed ID: 16188980
[TBL] [Abstract][Full Text] [Related]
40. Structure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type-1-specific compounds related to oxathiin carboxanilide.
Buckheit RW; Kinjerski TL; Fliakas-Boltz V; Russell JD; Stup TL; Pallansch LA; Brouwer WG; Dao DC; Harrison WA; Schultz RJ
Antimicrob Agents Chemother; 1995 Dec; 39(12):2718-27. PubMed ID: 8593008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
